The CRL issued by the FDA to Regeneron for extended EYLEA HD dosing to 24 weeks cited no safety or efficacy concerns. The US FDA has issued a complete response letter (CRL) to Regeneron ...

The sBLA for dupilumab (Dupixent) was supported by data from the phase 3 LIBERTY-CUPID clinical program in patients with uncontrolled CSU. On April 18, 2025, the FDA approved a resubmitted ...

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis. Welcome to this Contemporary Pediatrics poll. Take a look ...

Diazepam nasal spray (Valtoco) is approved for short-term treatment of seizure clusters, now in patients aged 2 years and older. On April 16, 2025, the FDA approved an expanded indication for diazepam ...

Proper hydration is a foundational—but often underemphasized—aspect of pediatric recovery. Whether a child is bouncing back from a febrile illness, a gastrointestinal virus, or even a mild respiratory ...

“Detecting and addressing potentially modifiable factors associated with healthy development is key to optimizing a child’s potential,” wrote the study authors, led by Inbal Goldshtein, PhD, of KI ...

In the United States, maralixibat (Livmarli; Mirum Pharmaceuticals) is approved to treat both ALGS and PFIC, now in liquid and tablet formulations. On April 14, 2025, the FDA approved a tablet ...

"Prior literature has explored the prevalence of motor impairments in autistic individuals, but estimates come from clinical, convenience, or small samples, limiting generalizability," stated the ...

In a newly-published randomized clinical trial, investigators found that 2 hours of mother-to-neonate skin-to-skin contact (SSC) in the delivery room did not affect neurodevelopment at age 2 to 3 ...

Poll: What's the diagnosis of this linear eruption on the leg of a 9-year-old girl?